Desmopressin (dDAVP) incident signals the need for enhanced monitoring protocols
Mary Jane Campigotto1, Christine Koczmara, Julie Greenall
1Institute for Safe Medication Practices Canada (ISMP Canada).
Abstract:
In this article, the authors highlight the circumstances surrounding the death of a young adult neurosurgical patient, recently reported to ISMP Canada. The incident signals the need for enhanced safeguards for patients receiving desmopressin (also known as dDAVP) and intravenous therapy. The authors present information from a recent ISMP Canada Safety Bulletin relevant to critical care, including an outline of potential contributing factors and suggested recommendations.
Related Concept Videos
Diabetes Insipidus I: Introduction
Diabetes Insipidus II: Pathophysiology
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Rheumatic Heart Disease IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
